This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. UPDATE: June 24, 2025: This article has been updated to ...

FDA classifies this as a Class I recall, which means using the device could result in adverse health effects or death. Dexcom Inc., has recalled its G4 Platinum and G5 Mobile continuous glucose ...

Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to ...

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for ...

VANCOUVER, Feb. 22, 2019 /CNW/ - Dexcom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), today announced that the company has received Health Canada approval for its next ...

Huons said on the 3rd it will provide free lending of the receiver for the continuous glucose monitor "Dexcom G7," which test-takers with type 1 diabetes can bring into College Scholastic Ability Test ...

ISTANBUL, Sept. 29, 2020 /PRNewswire/ -- DexCom, Inc. (NASDAQ: DXCM), a leader in continuous glucose monitoring (CGM) for people with diabetes, announced today market entry into Turkey, with the ...